<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25483672</PMID><DateCompleted><Year>2015</Year><Month>09</Month><Day>11</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>10</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice.</ArticleTitle><Pagination><StartPage>2885</StartPage><EndPage>2895</EndPage><MedlinePgn>2885-95</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4161/hv.29823</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV71) and Coxsackievirus A16 (CVA16) have caused severe epidemics of hand, foot and mouth disease (HFMD) in the Asia Pacific in recent years, particularly in infants and young children. This disease has become a serious public health problem, as no vaccines or antiviral drugs have been approved for EV71 and CA16 infections. In this study, we compared four monovalent vaccines, including formalin-inactivated EV71 virus (iEV71), EV71 virus-like particles (VLPs) (vEV71), formalin-inactivated CVA16 virus (iCVA16) and CVA16 VLPs (vCVA16), along with two bivalent vaccines, including equivalent doses of formalin-inactivated EV71+CVA16 virus (iEV71+iCVA16) and EV71+CVA16 VLPs (vEV71+vCVA16). The IgG titers and neutralization antibodies titers demonstrated that there are no immune interference exists between the two immunogens of EV71 and CVA16. IgG subclass isotyping revealed that IgG1 and IgG2b were induced primarily in all vaccine groups. Furthermore, cross-neutralization antibodies were elicited in mouse sera against other sub-genotypes of EV71 and CVA16. In vivo challenge experiments showed that the immune sera from vaccinated animals could confer passive protection to newborn mice against lethal challenge with 14 LD50 of EV71 and 50 LD50 of CVA16. Our results indicated that bivalent vaccination is promising for HFMD vaccine development. With the advantage of having a better safety profile than inactivated virus vaccines, VLPs should be used to combine both EV71 and CVA16 antigens as a candidate vaccine for prevention of HFMD virus transmission.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Shiyang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>a School of Life Sciences ; Jilin University ; Changchun , PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Liping</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zhenglun</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qunying</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Weiheng</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Huafei</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaojun</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Jun</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Lin</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Dandan</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Peihu</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Dong</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Ping</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Jingcai</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lv</LastName><ForeName>Xiuping</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Bo</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Fei</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Kong</LastName><ForeName>Wei</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Chunlai</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003384" MajorTopicYN="N">Coxsackievirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="N">Immunization, Passive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coxsackievirus A16</Keyword><Keyword MajorTopicYN="N">Enterovirus 71</Keyword><Keyword MajorTopicYN="N">HFMD</Keyword><Keyword MajorTopicYN="N">bivalent vaccines</Keyword><Keyword MajorTopicYN="N">monovalent vaccine</Keyword><Keyword MajorTopicYN="N">pseudovirus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25483672</ArticleId><ArticleId IdType="pmc">PMC5443096</ArticleId><ArticleId IdType="doi">10.4161/hv.29823</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Putnak JR, Phillips BA. Picornaviral structure and assembly. Microbiol Rev 1981; 45:287-315; PMID:7022155</Citation><ArticleIdList><ArticleId IdType="pmc">PMC281510</ArticleId><ArticleId IdType="pubmed">7022155</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimoto T, Chikahira M, Yoshida S, Ebira H, Hasegawa A, Totsuka A, Nishio O. Outbreak of central nervous system disease associated with hand, foot, and mouth disease in Japan during the summer of 2000: detection and molecular epidemiology of enterovirus 71. Microbiol Immunol 2002; 46:621-7; PMID:12437029; http://dx.doi.org/10.1111/j.1348-0421.2002.tb02743.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1348-0421.2002.tb02743.x</ArticleId><ArticleId IdType="pubmed">12437029</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, Wang JR, Shih SR; Taiwan Enterovirus Epidemic Working Group An epidemic of enterovirus 71 infection in Taiwan. N Engl J Med 1999; 341:929-35; PMID:10498487; http://dx.doi.org/10.1056/NEJM199909233411301</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199909233411301</ArticleId><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendig JW, Fleming DM. Epidemiological, virological, and clinical features of an epidemic of hand, foot, and mouth disease in England and Wales. Commun Dis Rep CDR Rev 1996; 6:R81-6; PMID:8664928</Citation><ArticleIdList><ArticleId IdType="pubmed">8664928</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert GL, Dickson KE, Waters MJ, Kennett ML, Land SA, Sneddon M. Outbreak of enterovirus 71 infection in Victoria, Australia, with a high incidence of neurologic involvement. Pediatr Infect Dis J 1988; 7:484-8; PMID:2841639; http://dx.doi.org/10.1097/00006454-198807000-00007</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006454-198807000-00007</ArticleId><ArticleId IdType="pubmed">2841639</ArticleId></ArticleIdList></Reference><Reference><Citation>Shekhar K, Lye MS, Norlijah O, Ong F, Looi LM, Khuzaiah R, Marzuki I, Hussein I, Wong SL, Mohan J, et al. . Deaths in children during an outbreak of hand, foot and mouth disease in Peninsular Malaysia&#x2013;clinical and pathological characteristics. Med J Malaysia 2005; 60:297-304; PMID:16379183</Citation><ArticleIdList><ArticleId IdType="pubmed">16379183</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao SW, Yin WD, Cun JP, Gao Q, Yin J, Liu GJ, Xu W. [Identification and characterization of enterovirus 71 isolated in Yunnan province]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2013; 27:263-5; PMID:24579470</Citation><ArticleIdList><ArticleId IdType="pubmed">24579470</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, MacDonald NE, Smith JC, Cai K, Yu H, Li H, Lei C. Severe enterovirus type 71 nervous system infections in children in the Shanghai region of China: clinical manifestations and implications for prevention and care. Pediatr Infect Dis J 2014; 33:482-7; PMID:24732390; http://dx.doi.org/10.1097/INF.0000000000000194</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000000194</ArticleId><ArticleId IdType="pubmed">24732390</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO 
WPRO Hand, Foot and Mouth Disease Situation Update, 08 January
2013. 
http://www.wpro.who.int/emerging_diseases/HFMD.Report.8Jan2013.pdf; Accessed 2013 Sptember 23.</Citation></Reference><Reference><Citation>McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 2002; 26:91-107; PMID:12007645; http://dx.doi.org/10.1111/j.1574-6976.2002.tb00601.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1574-6976.2002.tb00601.x</ArticleId><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwai M, Masaki A, Hasegawa S, Obara M, Horimoto E, Nakamura K, Tanaka Y, Endo K, Tanaka K, Ueda J, et al. . Genetic changes of coxsackievirus A16 and enterovirus 71 isolated from hand, foot, and mouth disease patients in Toyama, Japan between 1981 and 2007. Jpn J Infect Dis 2009; 62:254-9; PMID:19628900</Citation><ArticleIdList><ArticleId IdType="pubmed">19628900</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, He Y, Yang H, Zhu J, Xu X, Dong J, Zhu Y, Jin Q. Genetic characteristics of human enterovirus 71 and coxsackievirus A16 circulating from 1999 to 2004 in Shenzhen, People's Republic of China. J Clin Microbiol 2005; 43:3835-9; PMID:16081920; http://dx.doi.org/10.1128/JCM.43.8.3835-3839.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.43.8.3835-3839.2005</ArticleId><ArticleId IdType="pmc">PMC1233905</ArticleId><ArticleId IdType="pubmed">16081920</ArticleId></ArticleIdList></Reference><Reference><Citation>Ang LW, Koh BK, Chan KP, Chua LT, James L, Goh KT. Epidemiology and control of hand, foot and mouth disease in Singapore, 2001-2007. Ann Acad Med Singapore 2009; 38:106-12; PMID:19271036</Citation><ArticleIdList><ArticleId IdType="pubmed">19271036</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang CY, Li Lu F, Wu MH, Lee CY, Huang LM. Fatal coxsackievirus A16 infection. Pediatr Infect Dis J 2004; 23:275-6; PMID:15014311; http://dx.doi.org/10.1097/01.inf.0000115950.63906.78</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.inf.0000115950.63906.78</ArticleId><ArticleId IdType="pubmed">15014311</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu DS, Zhang Y, Chen JH, Duan LP, Zhao XH, Li XL, Sun Q, Chen X, Liu JF, Zheng YH, et al. . [Epidemiological features and pathogenic characteristics of hand, foot and mouth disease in Gansu Province, China during 2008-2012]. Bing Du Xue Bao 2014; 30:25-32; PMID:24772894</Citation><ArticleIdList><ArticleId IdType="pubmed">24772894</ArticleId></ArticleIdList></Reference><Reference><Citation>Goto K, Sanefuji M, Kusuhara K, Nishimura Y, Shimizu H, Kira R, Torisu H, Hara T. Rhombencephalitis and coxsackievirus A16. Emerg Infect Dis 2009; 15:1689-91; PMID:19861078; http://dx.doi.org/10.3201/eid1510.090594</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1510.090594</ArticleId><ArticleId IdType="pmc">PMC2866411</ArticleId><ArticleId IdType="pubmed">19861078</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W, Liu CF, Yan L, Li JJ, Wang LJ, Qi Y, Cheng RB, Xiong XY. Distribution of enteroviruses in hospitalized children with hand, foot and mouth disease and relationship between pathogens and nervous system complications. Virol J 2012; 9:8; PMID:22230340; http://dx.doi.org/10.1186/1743-422X-9-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-9-8</ArticleId><ArticleId IdType="pmc">PMC3268717</ArticleId><ArticleId IdType="pubmed">22230340</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Z. Severe hand, foot, and muoth disease caused by mixed infection of enterovirus 71 and coxsackie A16: report of 6 cases. Chin Gen 2011; Practice 14(10):3341-3346.</Citation></Reference><Reference><Citation>Yang F, Zhang T, Hu Y, Wang X, Du J, Li Y, Sun S, Sun X, Li Z, Jin Q. Survey of enterovirus infections from hand, foot and mouth disease outbreak in China, 2009. Virol J 2011; 8:508; PMID:22054534; http://dx.doi.org/10.1186/1743-422X-8-508</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-8-508</ArticleId><ArticleId IdType="pmc">PMC3227625</ArticleId><ArticleId IdType="pubmed">22054534</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W, Wu S, Xiong Y, Li T, Wen Z, Yan M, Qin K, Liu Y, Wu J. Co-circulation and genomic recombination of coxsackievirus A16 and enterovirus 71 during a large outbreak of hand, foot, and mouth disease in Central China. PLoS One 2014; 9:e96051; PMID:24776922; http://dx.doi.org/10.1371/journal.pone.0096051</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0096051</ArticleId><ArticleId IdType="pmc">PMC4002479</ArticleId><ArticleId IdType="pubmed">24776922</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JX, Mao QY, Liang ZL, Ji H, Zhu FC. Development of enterovirus 71 vaccines: from the lab bench to Phase III clinical trials. Expert Rev Vaccines 2014; 13:609-18; PMID:24621093; http://dx.doi.org/10.1586/14760584.2014.897617</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2014.897617</ArticleId><ArticleId IdType="pubmed">24621093</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Z, Mao Q, Gao F, Wang J. Progress on the research and development of human enterovirus 71 (EV71) vaccines. Front Med 2013; 7:111-21; PMID:23247645; http://dx.doi.org/10.1007/s11684-012-0237-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11684-012-0237-z</ArticleId><ArticleId IdType="pubmed">23247645</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y, Liu Q, Huang X, Li D, Ku Z, Zhang Y, Huang Z. Active immunization with a Coxsackievirus A16 experimental inactivated vaccine induces neutralizing antibodies and protects mice against lethal infection. Vaccine 2013; 31:2215-21; PMID:23499596; http://dx.doi.org/10.1016/j.vaccine.2013.03.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.03.007</ArticleId><ArticleId IdType="pubmed">23499596</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q, Wang Y, Gao R, Shao J, Yao X, Lang S, Wang C, Mao P, Liang Z, Wang J. A neonatal mouse model of coxsackievirus A16 for vaccine evaluation. J Virol 2012; 86:11967-76; PMID:22951825; http://dx.doi.org/10.1128/JVI.00902-12</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00902-12</ArticleId><ArticleId IdType="pmc">PMC3486452</ArticleId><ArticleId IdType="pubmed">22951825</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang E, Cheng C, Zhang Y, Wang J, Che Y, Pu J, Dong C, Liu L, He Z, Lu S, et al. . Comparative study of the immunogenicity in mice and monkeys of an inactivated CA16 vaccine made from a human diploid cell line. Hum Vaccin Immunother 2014; 10:10; PMID:24583556; http://dx.doi.org/10.4161/hv.28083</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.28083</ArticleId><ArticleId IdType="pmc">PMC4896597</ArticleId><ArticleId IdType="pubmed">24583556</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Yan K, Feng Y, Huang X, Ku Z, Cai Y, Liu F, Shi J, Huang Z. A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge. Vaccine 2012; 30:6642-8; PMID:22959985; http://dx.doi.org/10.1016/j.vaccine.2012.08.071</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.08.071</ArticleId><ArticleId IdType="pubmed">22959985</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H, Li HY, Han JF, Deng YQ, Li YX, Zhu SY, He YL, Qin ED, Chen R, Qin CF. Virus-like particles produced in Saccharomyces cerevisiae elicit protective immunity against Coxsackievirus A16 in mice. Appl Microbiol Biotechnol 2013; 97:10445-52; PMID:24085395; http://dx.doi.org/10.1007/s00253-013-5257-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00253-013-5257-3</ArticleId><ArticleId IdType="pubmed">24085395</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, Chou ST, Hu YC. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 2008; 26:1855-62; PMID:18329759; http://dx.doi.org/10.1016/j.vaccine.2008.01.058</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2008.01.058</ArticleId><ArticleId IdType="pubmed">18329759</ArticleId></ArticleIdList></Reference><Reference><Citation>Li HY, Han JF, Qin CF, Chen R. Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. Vaccine 2013; 31:3281-7; PMID:23726823; http://dx.doi.org/10.1016/j.vaccine.2013.05.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.05.019</ArticleId><ArticleId IdType="pubmed">23726823</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YC, Huang JH, Lai CW, Sheng HC, Shih SR, Ho MS, Hu YC. Expression, purification and characterization of enterovirus-71 virus-like particles. World J Gastroenterol 2006; 12:921-7; PMID:16521221</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066158</ArticleId><ArticleId IdType="pubmed">16521221</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Fan P, Jin J, Su W, An D, Xu L, Sun S, Zhang Y, Meng X, Gao F, et al. . Establishment of cell lines with increased susceptibility to EV71/CA16 by stable overexpression of SCARB2. Virol J 2013; 10:250; PMID:23919614; http://dx.doi.org/10.1186/1743-422X-10-250</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-10-250</ArticleId><ArticleId IdType="pmc">PMC3765843</ArticleId><ArticleId IdType="pubmed">23919614</ArticleId></ArticleIdList></Reference><Reference><Citation>Curry S, Fry E, Blakemore W, Abu-Ghazaleh R, Jackson T, King A, Lea S, Newman J, Stuart D. Dissecting the roles of VP0 cleavage and RNA packaging in picornavirus capsid stabilization: the structure of empty capsids of foot-and-mouth disease virus. J Virol 1997; 71:9743-52; PMID:9371640</Citation><ArticleIdList><ArticleId IdType="pmc">PMC230284</ArticleId><ArticleId IdType="pubmed">9371640</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuta K, Aoki Y, Suto A, Ootani K, Katsushima N, Itagaki T, Ohmi A, Okamoto M, Nishimura H, Matsuzaki Y, et al. . Cross-antigenicity among EV71 strains from different genogroups isolated in Yamagata, Japan, between 1990 and 2007. Vaccine 2009; 27:3153-8; PMID:19446185; http://dx.doi.org/10.1016/j.vaccine.2009.03.060</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2009.03.060</ArticleId><ArticleId IdType="pubmed">19446185</ArticleId></ArticleIdList></Reference><Reference><Citation>Bek EJ, Hussain KM, Phuektes P, Kok CC, Gao Q, Cai F, Gao Z, McMinn PC. Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection. Vaccine 2011; 29:4829-38; PMID:21550375; http://dx.doi.org/10.1016/j.vaccine.2011.04.070</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.04.070</ArticleId><ArticleId IdType="pubmed">21550375</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P, Guo MS, Lin FH, Hsiao KN, Weng SY, Chou AH, Wang JR, Hsieh SY, Su IJ, Liu CC. Immunological and biochemical characterization of coxsackie virus A16 viral particles. PLoS One 2012; 7:e49973; PMID:23226233; http://dx.doi.org/10.1371/journal.pone.0049973</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0049973</ArticleId><ArticleId IdType="pmc">PMC3511423</ArticleId><ArticleId IdType="pubmed">23226233</ArticleId></ArticleIdList></Reference><Reference><Citation>Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Estes MK. Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin Immunol 2003; 108:241-7; PMID:14499247; http://dx.doi.org/10.1016/S1521-6616(03)00120-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1521-6616(03)00120-7</ArticleId><ArticleId IdType="pubmed">14499247</ArticleId></ArticleIdList></Reference><Reference><Citation>Paavonen J, Jenkins D, Bosch FX, Naud P, Salmer&#xf3;n J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, et&#xa0;al.; HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161-70; PMID:17602732; http://dx.doi.org/10.1016/S0140-6736(07)60946-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(07)60946-5</ArticleId><ArticleId IdType="pubmed">17602732</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Ma Y, Wang H, Liu Q. Quantitative evaluation of the effect of the hepatitis B vaccine based on the HBsAg- and anti-HBs-positive rates in the Chinese population over the last 33&#xa0;years. Vaccine 2012; 30:3483-7; PMID:22433962; http://dx.doi.org/10.1016/j.vaccine.2012.02.053</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.02.053</ArticleId><ArticleId IdType="pubmed">22433962</ArticleId></ArticleIdList></Reference><Reference><Citation>
http://www.clinicaltrials.gov
(Identifier NCT01897701).</Citation></Reference><Reference><Citation>Cai Y, Ku Z, Liu Q, Leng Q, Huang Z. A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses. Vaccine 2014; 32:2406-12; PMID:24657161; http://dx.doi.org/10.1016/j.vaccine.2014.03.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.03.012</ArticleId><ArticleId IdType="pubmed">24657161</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Peng W, Ren J, Hu Z, Xu J, Lou Z, Li X, Yin W, Shen X, Porta C, et al. . A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol 2012; 19:424-9; PMID:22388738; http://dx.doi.org/10.1038/nsmb.2255</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2255</ArticleId><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>Shingler KL, Yoder JL, Carnegie MS, Ashley RE, Makhov AM, Conway JF, Hafenstein S. The enterovirus 71 A-particle forms a gateway to allow genome release: a cryoEM study of picornavirus uncoating. PLoS Pathog 2013; 9:e1003240; PMID:23555253; http://dx.doi.org/10.1371/journal.ppat.1003240</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003240</ArticleId><ArticleId IdType="pmc">PMC3605244</ArticleId><ArticleId IdType="pubmed">23555253</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt NJ, Lennette EH, Ho HH. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis 1974; 129:304-9; PMID:4361245; http://dx.doi.org/10.1093/infdis/129.3.304</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/129.3.304</ArticleId><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown BA, Oberste MS, Alexander JP, Jr., Kennett ML, Pallansch MA. Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. J Virol 1999; 73:9969-75; PMID:10559310</Citation><ArticleIdList><ArticleId IdType="pmc">PMC113047</ArticleId><ArticleId IdType="pubmed">10559310</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang YP, Lin TL, Kuo CY, Lin MW, Yao CY, Liao HW, Hsu LC, Yang CF, Yang JY, Chen PJ, et al. . The circulation of subgenogroups B5 and C5 of enterovirus 71 in Taiwan from 2006 to 2007. Virus Res 2008; 137:206-12; PMID:18706461; http://dx.doi.org/10.1016/j.virusres.2008.07.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2008.07.015</ArticleId><ArticleId IdType="pubmed">18706461</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu H, Utama A, Onnimala N, Li C, Li-Bi Z, Yu-Jie M, Pongsuwanna Y, Miyamura T. Molecular epidemiology of enterovirus 71 infection in the Western Pacific Region. Pediatr Int 2004; 46:231-5; PMID:15056257; http://dx.doi.org/10.1046/j.1442-200x.2004.01868.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1442-200x.2004.01868.x</ArticleId><ArticleId IdType="pubmed">15056257</ArticleId></ArticleIdList></Reference><Reference><Citation>Urquhart GE. A survey of coxsackie A16 virus antibodies in human sera. J Hyg (Lond) 1984; 93:205-12; PMID:6094661; http://dx.doi.org/10.1017/S002217240006472X</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S002217240006472X</ArticleId><ArticleId IdType="pmc">PMC2129431</ArticleId><ArticleId IdType="pubmed">6094661</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Wang D, Yan D, Zhu S, Liu J, Wang H, Zhao S, Yu D, Nan L, An J, et al. . Molecular evidence of persistent epidemic and evolution of subgenotype B1 coxsackievirus A16-associated hand, foot, and mouth disease in China. J Clin Microbiol 2010; 48:619-22; PMID:20018819; http://dx.doi.org/10.1128/JCM.02338-09</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.02338-09</ArticleId><ArticleId IdType="pmc">PMC2815627</ArticleId><ArticleId IdType="pubmed">20018819</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W, Guo H, Li J, Ren S, Wei Z, Bao W, Hu X, Zhao K, Zhang W, Zhou Y, et al. . Circulating HFMD-associated coxsackievirus A16 is genetically and phenotypically distinct from the prototype CV-A16. PLoS One 2014; 9:e94746; PMID:24736564; http://dx.doi.org/10.1371/journal.pone.0094746</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0094746</ArticleId><ArticleId IdType="pmc">PMC3988102</ArticleId><ArticleId IdType="pubmed">24736564</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin J, Xu L, Guo S, Sun S, Zhang S, Zhu C, Kong W, Jiang C. Safe and Objective Assay of Enterovirus 71 Neutraliziong Antibodies Via Pseudovirus. CHEM RES CHINESE UNIVERSITIES 28, 91-95 2012.</Citation></Reference><Reference><Citation>Wu X, Mao Q, Yao X, Chen P, Chen X, Shao J, Gao F, Yu X, Zhu F, Li R, et al. . Development and evaluation of a pseudovirus-luciferase assay for rapid and quantitative detection of neutralizing antibodies against enterovirus 71. PLoS One 2013; 8:e64116; PMID:23755115; http://dx.doi.org/10.1371/journal.pone.0064116</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0064116</ArticleId><ArticleId IdType="pmc">PMC3673970</ArticleId><ArticleId IdType="pubmed">23755115</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Tan XJ, Wang HY, Yan DM, Zhu SL, Wang DY, Ji F, Wang XJ, Gao YJ, Chen L, et al. . An outbreak of hand, foot, and mouth disease associated with subgenotype C4 of human enterovirus 71 in Shandong, China. J Clin Virol 2009; 44:262-7; PMID:19269888; http://dx.doi.org/10.1016/j.jcv.2009.02.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2009.02.002</ArticleId><ArticleId IdType="pubmed">19269888</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F, Ren L, Xiong Z, Li J, Xiao Y, Zhao R, He Y, Bu G, Zhou S, Wang J, et al. . Enterovirus 71 outbreak in the People's Republic of China in 2008. J Clin Microbiol 2009; 47:2351-2; PMID:19439545; http://dx.doi.org/10.1128/JCM.00563-09</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00563-09</ArticleId><ArticleId IdType="pmc">PMC2708525</ArticleId><ArticleId IdType="pubmed">19439545</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan X, Huang X, Zhu S, Chen H, Yu Q, Wang H, Huo X, Zhou J, Wu Y, Yan D, et al. . The persistent circulation of enterovirus 71 in People's Republic of China: causing emerging nationwide epidemics since 2008. PLoS One 2011; 6:e25662; PMID:21980521; http://dx.doi.org/10.1371/journal.pone.0025662</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0025662</ArticleId><ArticleId IdType="pmc">PMC3181342</ArticleId><ArticleId IdType="pubmed">21980521</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;n J, Crossland G, Wood DJ, Minor PD. Characterization of formaldehyde-inactivated poliovirus preparations made from live-attenuated strains. J Gen Virol 2003; 84:1781-8; PMID:12810872; http://dx.doi.org/10.1099/vir.0.19088-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.19088-0</ArticleId><ArticleId IdType="pubmed">12810872</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong KC, Devi S, Cardosa MJ, Wong KT. Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. J Virol 2010; 84:661-5; PMID:19864378; http://dx.doi.org/10.1128/JVI.00999-09</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00999-09</ArticleId><ArticleId IdType="pmc">PMC2798416</ArticleId><ArticleId IdType="pubmed">19864378</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong C, Liu L, Zhao H, Wang J, Liao Y, Zhang X, Na R, Liang Y, Wang L, Li Q. Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys. Vaccine 2011; 29:6269-75; PMID:21722686; http://dx.doi.org/10.1016/j.vaccine.2011.06.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.06.044</ArticleId><ArticleId IdType="pubmed">21722686</ArticleId></ArticleIdList></Reference><Reference><Citation>Krah DL. A simplified multiwell plate assay for the measurement of hepatitis A virus infectivity. Biologicals 1991; 19:223-7; PMID:1659431; http://dx.doi.org/10.1016/1045-1056(91)90039-M</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/1045-1056(91)90039-M</ArticleId><ArticleId IdType="pubmed">1659431</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>